The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Lilly’s new approach to cholesterol. Eli Lilly’s experimental cholesterol drug doubled patients’ HDL (Opens in a new window), or good cholesterol, setting the stage for a race between the ...

Eli Lilly (LLY) shares rallied 14.3% in the last trading session to close at $839.96. ... Merck's consensus EPS estimate for the upcoming report has changed -4% over the past month to $2.16.

Eli Lilly and Co. LLY fell 18% in May, its steepest monthly drop since February 2009. ... UnitedHealth Group is expected to rise by 18%, while Merck & Co. is forecasted 27% higher the next 12 months.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

A cautious culture cost Novo its obesity lead. Danish drugmaker Novo Nordisk was the first to sell a new generation of GLP-1 obesity drugs, but it’s now widely seen as trailing Eli Lilly.

(Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly ...